Clinical Trial Detail

NCT ID NCT03768531
Title Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Indications

biliary tract cancer

Therapies

Cabiralizumab + Nivolumab

Nivolumab

Age Groups: senior adult

No variant requirements are available.